First Turn Management LLC Invests $25.02 Million in IDEAYA Biosciences, Inc. $IDYA

Posted by Brenda Bartman on Jun 14th, 2026

First Turn Management LLC purchased a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 723,653 shares of the company’s stock, valued at approximately $25,017,000. IDEAYA Biosciences makes up about 2.9% of First Turn Management LLC’s holdings, making the stock its 18th largest position. First Turn Management LLC owned about 0.83% of IDEAYA Biosciences as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of IDEAYA Biosciences by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock worth $173,518,000 after buying an additional 97,116 shares in the last quarter. State Street Corp raised its holdings in shares of IDEAYA Biosciences by 27.6% during the 4th quarter. State Street Corp now owns 4,134,641 shares of the company’s stock worth $142,935,000 after buying an additional 893,707 shares in the last quarter. Baker BROS. Advisors LP raised its holdings in shares of IDEAYA Biosciences by 54.6% during the 3rd quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock worth $89,125,000 after buying an additional 1,156,716 shares in the last quarter. Fiera Capital Corp raised its holdings in shares of IDEAYA Biosciences by 32.6% during the 4th quarter. Fiera Capital Corp now owns 2,437,262 shares of the company’s stock worth $84,256,000 after buying an additional 599,295 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of IDEAYA Biosciences by 43.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,770,866 shares of the company’s stock worth $61,219,000 after buying an additional 537,753 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Guggenheim boosted their price objective on IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Mizuho reduced their price objective on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Friday, May 22nd. Wells Fargo & Company boosted their price objective on IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Tuesday, April 21st. Fifteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $50.69.

View Our Latest Research Report on IDEAYA Biosciences

IDEAYA Biosciences Stock Up 0.5%

Shares of IDYA stock opened at $28.98 on Friday. The firm has a market capitalization of $2.55 billion, a P/E ratio of -18.11 and a beta of -0.05. IDEAYA Biosciences, Inc. has a twelve month low of $20.50 and a twelve month high of $39.28. The stock’s fifty day simple moving average is $29.89 and its 200 day simple moving average is $32.49.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million during the quarter, compared to analyst estimates of $5.04 million. The firm’s revenue was down 39.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.82) EPS. As a group, equities research analysts expect that IDEAYA Biosciences, Inc. will post -4.27 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

(Free Report)

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.